Last reviewed · How we verify
Natacyn (NATAMYCIN)
Natacyn (Natamycin) is a polyene antimicrobial small molecule developed by Alcon and currently owned by Harrow Eye. It is FDA-approved since 1978 for treating fungal blepharitis, conjunctivitis, and keratitis. As an off-patent medication, it is not commercially available as a generic. Natacyn works by binding to ergosterol in fungal cell membranes, disrupting their integrity and ultimately leading to cell death. It is a critical treatment option for ocular fungal infections.
At a glance
| Generic name | NATAMYCIN |
|---|---|
| Sponsor | Harrow Health |
| Drug class | Polyene Antimicrobial [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1978 |
Approved indications
- Fungal Blepharitis
- Fungal conjunctivitis
- Fungal keratitis
Common side effects
- allergic reaction
- change in vision
- chest pain
- corneal opacity
- dyspnea
- eye discomfort
- eye edema
- eye hyperemia
- eye irritation
- eye pain
- foreign body sensation
- parethesia
Key clinical trials
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction (PHASE3)
- Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis (PHASE2)
- Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A (PHASE3)
- Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers (PHASE3)
- Cross-linking for Corneal Ulcers Treatment Trial (PHASE3)
- Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis (PHASE3)
- The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study
- The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Natacyn CI brief — competitive landscape report
- Natacyn updates RSS · CI watch RSS
- Harrow Health portfolio CI